AspenBio Pharma (APPY) announces a secondary offering for an undisclosed amount of its common stock. The company intends to use the net proceeds for general corporate purposes, which includes conducting a clinical trial for its blood-based appendicitis test, and for working capital purposes. Aegis Capital is acting as the sole book-running manager for the offering. Shares -8.5% AH.
AspenBio Pharma (APPY) announces a secondary offering for an undisclosed amount of its common...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs